Investigators Review Marketed Adalimumab Biosimilars for Switching Differences

Polpharma Biologics Executives Discuss Ranibizumab Biosimilar and Other Product Candidates

October 13th 2021

The Center for Biosimilars® speaks with Polpharma Biologics executives Alex Moulson, vice president of Development, and Pawel Lewinski, head of Portfolio and Commercial Strategy, about the company's biosimilar pipeline.

EU Commission Enters Comment Phase of Plan to Improve Pharmaceutical Competition, Access

October 12th 2021

By Tony Hagen

The European Commission is collecting comment on its multifaceted blueprint for broadening access to biologics and generic drugs and stimulating competition.

Ivo Abraham, PhD, Discusses G-CSF Biosimilars, Such as Neulasta Onpro

October 11th 2021

By Skylar Jeremias

Ivo Abraham, PhD, a professor with University of Arizona Health Sciences in the Department of Pharmacy Practice, outlines the current trajectory and savings potential for granulocyte-colony stimulating factor (G-CSF) biosimilars and Neulasta Onpro (pegfilgrastim).

Not So Different: Tactics for Increasing Patient and Provider Confidence in Biosimilars

October 10th 2021

Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, explains how his practice has worked to inform patients and providers about biosimilars and improve their confidence in the utilization of biosimilars.

Milestones Reported for Bevacizumab Biosimilars in China, Canada

October 9th 2021

Biosimilar development companies report an approval in Canada and positive phase 3 findings in China for their bevaciumab biosimilars.

The Top 5 Biosimilar Articles for the Week of October 4

October 8th 2021

Here are the top 5 biosimilar articles for the week of October 4, 2021.

Court Dismisses AbbVie's Trade Secret Piracy Case Against Alvotech

October 7th 2021

By Tony Hagen

A US District Court in Illinois has ruled that although trade secret theft may have occurred over an adalimumab biosimilar candidate, it happened far from the state. With only a very "attenuated" connection, there are no grounds to bring action against Alvotech in the case of purloined manufacturing data, the judge stated.

Twelve-Month Court Battle Will Delay Adalimumab Biosimilar Launch for Alvotech

October 6th 2021

By Tony Hagen

The court battle between AbbVie and Alvotech could be a defining victory in the struggle to bring biosimilar versions of adalimumab to market, but a yearlong court process must play out first.

Coherus BioSciences Reaches Clinical and Regulatory Milestones for Udenyca and CHS-201

October 6th 2021

By Tony Hagen

Positive findings for Coherus BioSciences' ranibizumab candidate (CHS-201) were presented at the Scientific Meeting of the Retina Society, and the company said equivalence end points were met for an on-body injector version of Udenyca (pegfilgrastim).

Canadian Experts Offer Switching Guidance for Biosimilars in Rheumatology

October 5th 2021

By Tony Hagen

Preventing the nocebo effect requires a demonstration of confidence in biosimilars from all health care practitioners, including pharmacists, experts said in a newly published rheumatology treatment guidance document.